Global Business Reports: Interview with Altasciences' CEO, Chris Perkin
The Bioequivalence of Fixed-Dose Combination Tablets of Bisoprolol and Ramipril and its Drug-Drug Interaction Potential
ISSUE NO. 19 — Hallucinogens, Psychedelics, Entactogens: Challenges Associated With Schedule 1 Therapeutic Development
AAPS Outsourcing Newsletter (Issue III): Spotlight on Dr. Anahita Keyhani, PhD, Senior Director of Scientific Operations, Mass Spectrometry, at Altasciences
CTS Clinical and Translational Science: The Bioequivalence of Fixed-Dose Combination Tablets of Bisoprolol and Ramipril and its Drug-Drug Interaction Potential
The Many Faces of Recreational Drug Use
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
The Issue of Opioid aBUSE
A growing public health concern, opioid abuse has been intensified by the COVID-19 pandemic.
The Next Trip with Altasciences and DevelRX
In this podcast episode, experts from Altasciences and DevelRX examine the preclinical, clinical, and regulatory requirements and strategies that second generation psychedelics may utilize to differentiate their pharmacological profile, and strategically demonstrate efficacy and safety data that may differentiate from first generation candidates. The discussion is moderated by Altasciences' Chief Scientific Officer, Dr. Beatrice Setnik.
The potential use of psychedelics for the treatment of various CNS indications is currently under active investigation.
ISSUE NO. 18 — Planning Your First-in-Human Trial
The Many Faces of Recreational Drug Use - Episode 1
Drug addiction is a devastating condition that affects the quality of the user and their families. In this podcast series, we explore the behaviors of individuals who abuse opioids and stimulants, and learn about their patterns of use and motivations to compel them to continue using these drugs through a series of candid interviews with opioid and stimulant recreational drug users.